Singapore-based startup ChemT Biotechnology is tackling pharmaceutical industry bottlenecks to bring efficiencies to the manufacturing of advanced medicines. The company is solving a simple but oft overlooked problem. While AI has transformed drug discovery, the manufacturing of biologics still relies on unpredictable yields, long development timelines, and processes that break down when scaled up.
Traditional drugs are chemically synthesized with small, simple, predictable molecular structures. Biologics are large, intricate proteins or sugars that cannot be replicated by chemical processes. So at the core of ChemT’s approach is CelMo™an AI-driven virtual cell platform trained on billions of proprietary biological sequencing reads and validated in the lab. The setup simulates how cells respond to manufacturing conditions, genetic changes and other stresses. Rather than building lab automation tools or discovery software (of which there are many already), ChemT builds intelligence directly into the manufacturing process itself. In commonly used cell lines for example, the platform has demonstrated a 50% increased output and a 40% reduction in production timelines. Flagship product Chemplify™applies the same logic to T-cell manufacturing for cancer therapies, showing 50% faster development, 3× scalability, 60% lower costs and 10× higher cell expansion yield.
These impressive figures allowed ChemT to recently close a US$4 million seed round led by Wavemaker Ventures, with participation from SEEDS, an arm of SG Growth Capital. 360 Health, Draper University Ventures and Temasek Life Sciences Accelerator also participated, bringing total funding to $5 million within 18 months, including $1 million in angel investment. Wavemaker’s participation is interesting. Their thesis of backing capital-efficient deep tech and enterprise solutions that drive massive efficiency gains, aligns snugly with ChemT. Wavemaker also evaluates their portfolio against UN Sustainable Development Goals (SDGs). ChemT fits into this framework through a few crucial sustainability and resource-efficiency levers.
Traditional bio-manufacturing, such as growing cells to make antibodies, therapeutics or advanced material, is an incredibly resource-intensive process. Bioreactors consume vast amounts of water, energy and nutrients over long operational cycles. But ChemT Biotechnology cuts down processing timelines by nearly half, directly eliminating massive amounts of energy consumption and operational waste. This effectively shrinks the carbon and environmental footprint per unit of output. Bio-manufacturing has historically also had a massive bottleneck because cell behavior inside a bioreactor is notoriously unpredictable. ChemT solves this using precision small molecules to steer cell behaviour instead of relying purely on hardware scaling or brute-force lab automation. This means companies can drastically increase production yield without needing to construct massive new chemical or biological manufacturing plants.
The company has a stellar lineup of founders and advisors, several of whom have deep connections into immunological research in Singapore and the United States. CEO Jie Sun is a health data scientist who previously co-founded Basys.ai, a healthtech startup backed by the Mayo Clinic and Eli Lilly. ChemT’s initial commercial rollout is heavily focused on life sciences and advanced cancer therapies (via their Chemplify™small molecule product), the intelligence layer they are building for cellular systems arguably lays the groundwork for future efficiencies across Singapore’s $40B+ annual bioeconomy production. The same virtual cell simulation technology can be applied down the road to optimise cellular systems used in alternative proteins, bio-materials, and bio-chemicals.
Genius ReFi connects researchers, entrepreneurs, investors and industry to build high value science-based ventures.
Join our mailing list or participate in the free Genius ReFi innovator community on Discord.
Image credit: Renea Mackie
